Preventing Serogroup B Meningococcal Disease

In a phase IIB/III study conducted among adolescents in Chile, a multicomponent vaccine — 4CMenB — was immunogenic and safe.

Licensed vaccines are available to protect against meningococcal serogroups A, C, W-135, and Y. Although serogroup B infrequently affects individuals aged >1 year in the U.S., it remains a major cause of meningococcal disease worldwide. Development of a vaccine against this serogroup has been challenging, however, because serogroup B polysaccharide resembles the human neural-cell adhesion molecule and is poorly immunogenic. Investigators have now developed a candidate vaccine, 4CMenB, with four components: three semiconserved surface protein antigens plus a serogroup B outer membrane vesicle preparation.

In a recent manufacturer-sponsored, observer-blind, placebo-controlled, phase IIB/III trial conducted in Chile, investigators examined the …

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Preventing Serogroup B Meningococcal Disease

Topics

Reviewing Author